


The background of the slide features a grayscale image of an antibody molecule, a complex protein structure with multiple binding sites. Overlaid on this are several white, five-pointed stars arranged in a circular pattern, reminiscent of the European Union flag. The text is positioned in the lower-left quadrant of the image.

FCF Fox Corporate Finance | FCF Life Sciences
Life Sciences Venture Capital Monitor – Europe

April 2023

Antibody

**FCF LIFE SCIENCES
OVERVIEW**



Overview



Focus on Biotech, MedTech and HealthTech

We advise innovative companies on arranging, structuring and placing equity, debt, and licensing transactions in a holistic financing approach



Focus Areas

FCF advises on the following transaction types:



FCF Life Sciences
advises leading Life Sciences companies in Europe in financing transactions

Over **EUR 2bn** Life Sciences transaction volume
(Professionals and Advisors)

Life Sciences Team of **>12**

Over **100** years in aggregated Life Sciences experience

Access to **> 1,500** international investors

Company Valuation
in partnership with **BioScience Valuation GmbH**

China Licensing
in partnership with **YAFO Capital**

Leading EIB advisor in Europe

Over **80** completed Life Sciences transactions
(Professionals and Advisors)

8 regularly published Life Sciences reports

Life Sciences Team



Dr. Alexandra Goll
Advisor – Venture Capital



Dr. Axel Polack
Advisor – Science & Technology



Claus Schalper
Advisor – Corporate Affairs



Dr. Mathias Schott
Advisor – Life Sciences



Johannes Link
Life Sciences Banking – Europe



Marcel Christou
Life Sciences Banking – Europe



Enno Spillner
Advisor – Capital Markets



Dr. Joachim M. Greuel
Advisor – Valuations



Prof. Dr. Horst Domdey
Advisor – Science & Technology



Zaid Maleh
Life Sciences Banking – Dubai



Sean Jian, CFA
Life Sciences Banking – China



Services

- ✓ Integrated Financial Modelling
- ✓ Investor Screening
- ✓ Management Presentation
- ✓ Post-Transaction Support
- ✓ Due Diligence Support
- ✓ Financing Strategy Advisory
- ✓ Investor / IR Roadshow
- ✓ Equity & Debt Fundraising
- ✓ Term Sheet Negotiation
- ✓ Life Science Advisory Board
- ✓ Closing Assistance
- ✓ IPO Execution Support

(extract from service portfolio)

Our capital markets research feeds our proprietary investor database

Data Collection

Life Sciences Venture Capital Monitor – Europe



- Venture Capital
- Life Sciences*
- Focus on Europe

Biotech Venture Capital Monitor – US



- Venture Capital
- Life Sciences
- Focus on the US

Life Sciences Venture Capital Report



- Venture Capital
- Life Sciences
- Focus on Europe and the US

Biotech Licensing Monitor – China



- Licensing
- Biotech
- Focus on Europe and Chinese licensors

Biotech Public Equity Monitor



- Public Equity
- Biotech
- Focus on Europe

MedTech Public Equity Monitor



- Public Equity
- MedTech
- Focus on Europe

Life Sciences IPO Report



- IPOs
- Life Sciences
- Focus on Europe and the US

Life Sciences SPAC Monitor



- SPACs
- Life Sciences
- Focus on US / Europe and US SPACs


Market Monitoring

Data Processing

- Transaction data
- Investment preferences

Proprietary Investor Database

- Most comprehensive database
- > 1,300,000 data points



Constant Data Enrichment

- Ongoing investor communication
- Data validation

Data-driven Investor Selection

1
2
3

- Intelligent search algorithms
- Big data sequencing

Executive Summary

The FCF Life Sciences Venture Capital Monitor - Europe is a monthly published overview focusing on the venture capital financing environment in the Biotech, Pharmaceutical, MedTech and HealthTech segments, and can be used as a quick reference for investors, corporates and professionals

More advanced, detailed and / or customized reports are available upon request

FCF Life Sciences Venture Capital Monitor - Europe

is a monthly published overview of Biotech, Pharmaceutical, MedTech and HealthTech companies, displaying venture capital financing trends in the European life science industry

Scope

The selection of companies is based on the following criteria:

- Focus on transactions with European headquartered life science companies and available deal volume
- Companies operating in the Biotech, Pharmaceutical, MedTech, HealthTech, Services or other life science related sectors
- The Biotech sector is further divided into the following therapy areas / indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information

Recipients

The FCF Life Sciences Venture Capital Monitor - Europe targets the following recipients:

- Corporates / Executives
- Institutional investors
- Private equity investors
- Venture capital investors
- Family Offices / High-net-worth individuals
- Advisors

Availability

The FCF Life Sciences Venture Capital Monitor - Europe is available on FCF's website at "<https://www-fcf-de/de/life-sciences/>"


Data

All input data is provided by Pitchbook or GlobalData and is not independently verified by FCF- Ratio and multiple calculations are driven based on the input data available- For additional information and disclaimer, please refer to the last page

If you have questions, comments or ideas, please do not hesitate to contact us


**EUROPEAN VENTURE CAPITAL
TRANSACTIONS IN LIFE SCIENCES**

APRIL 2023




Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

| # | Company | HQ | Deal Volume | Series |
|---|----------------------|----|-------------|--------|
| 1 | Distalmotion | CH | 138 | F |
| 2 | Amolyt Pharma | FR | 130 | C |
| 3 | Hemab Therapeutics | DK | 125 | B |
| 4 | Noema Pharma | CH | 104 | B |
| 5 | Alentis Therapeutics | CH | 97 | C |

Top 5 Investors

| # | Investor | HQ | Deal Volume ² | # of Deals |
|---|----------------------------------|----|--------------------------|------------|
| 1 | Revival Healthcare Capital | US | 138 | 1 |
| 2 | Novo Holdings | DK | 64 | 5 |
| 3 | Gilde Healthcare Partners | DK | 55 | 4 |
| 4 | European Innovation Council Fund | DE | 48 | 9 |
| 5 | Jeito | DK | 46 | 3 |

| # | Date | Company | HQ | Subsector | Vertical - Indication / Stage | Company Description | Deal Series | Deal Volume (EURm) | Total Raised (EURm) | Deal Synopsis |
|---|------------|---------------------|-----|---------------------|--|--|-------------|--------------------|---------------------|---|
| 1 | 30.04.2023 | Loop Diagnostics | ESP | MedTech | Diagnostic Device / On market | Development of diagnostic devices designed for early detection and diagnosis of sepsis. | A | < 1 | < 1 | The company raised EUR 625,000 of equity crowdfunding on April 30, 2023. |
| 2 | 28.04.2023 | Pattern BioSciences | CHE | Biotech / Pharma | Oncology / Developing | Developer of biotechnology platform designed for cancer treatment. | C | 26 | 61 | The company raised \$28.7 million of Series C venture funding on April 28, 2023. The funds will be used to complete the development of its infectious disease diagnostic platform, perform clinical validation studies, and submit data for the platform. |
| 3 | 27.04.2023 | Biow | ESP | MedTech | Sleep Improvement Device / On market | Developer of cellular regeneration system designed to improve the health and well-being of people. | A | 5 | 5 | The company raised EUR 5 million of venture funding on April 27, 2023. The funds will be used to boost its biomedical research to fight aging and launch the company in the insurance verticals, as well as in other adjacent ones (residences, hotels, or corporate headquarters). |
| 4 | 26.04.2023 | TympaHealth | GBR | MedTech | Medical Device / On market | Operator of a hearing platform intended to help the world to hear. | A | 21 | 33 | The company raised \$23 million of Series A venture funding on April 26, 2023, putting the company's pre-money valuation at \$36.15 million. The funds will be used to grow the team size and expand its services in the UK and Continental Europe in tandem with a planned US market entry. |
| 5 | 26.04.2023 | HydRegen | GBR | Healthcare Services | Bio-Based Manufacturing / On market | Developer of bio-based manufacturing technologies designed to manufacture clean, safe and sustainable chemicals. | C | 3 | 4 | The company raised GBP 2.6 million of venture funding on April 26, 2023. The funds will be used for the commercial development and deployment of its technologies through the next 18 months, and to expand its team over the next 12 months. |
| 6 | 26.04.2023 | Gossik | CHE | Healthcare Services | ADHD Coaching Services / On market | Developer of an AI-based assistant designed to support children in everyday life with self-organization. | A | 1 | 1 | The company raised CHF 1 million of venture funding on April 26, 2023, putting the company's pre-money valuation at an estimated CHF 2.93 million. The funds will be used for further development and scalability of the digital assistant and into the expansion of the accompanying offer. |
| 7 | 26.04.2023 | Medicai | ROU | HealthTech | Healthcare Management Platform / On market | Developer of an imaging platform designed to facilitate sharing and communication between patients, doctors, clinics, and hospitals. | C | < 1 | 1 | The company raised \$90,290 of venture funding in the form of SAFE Notes on April 26, 2023. |
| 8 | 25.04.2023 | Ciliatech | FRA | MedTech | Intraocular Implant / On market | Developer of intraocular implant designed for the treatment of glaucoma. | A | 4 | 5 | The company raised EUR 3.5 million of venture funding through a combination of debt and equity on April 25, 2023. The funds will be used to achieve key R&D milestones and fulfil the regulatory affairs requirements to obtain CE mark approval by the end of 2024 and will also continue its clinical research program. |


Source: PitchBook as of 05-05-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

| # | Company | HQ | Deal Volume | Series |
|---|----------------------|----|-------------|--------|
| 1 | Distalmotion | CH | 138 | F |
| 2 | Amolyt Pharma | FR | 130 | C |
| 3 | Hemab Therapeutics | DK | 125 | B |
| 4 | Noema Pharma | CH | 104 | B |
| 5 | Alentis Therapeutics | CH | 97 | C |

Top 5 Investors

| # | Investor | HQ | Deal Volume ² | # of Deals |
|---|----------------------------------|----|--------------------------|------------|
| 1 | Revival Healthcare Capital | US | 138 | 1 |
| 2 | Novo Holdings | DK | 64 | 5 |
| 3 | Gilde Healthcare Partners | DK | 55 | 4 |
| 4 | European Innovation Council Fund | DE | 48 | 9 |
| 5 | Jeito | DK | 46 | 3 |

| # | Date | Company | HQ | Subsector | Vertical - Indication / Stage | Company Description | Deal Series | Deal Volume (EURm) | Total Raised (EURm) | Deal Synopsis |
|----|------------|-------------------|-----|---------------------|---------------------------------------|---|-------------|--------------------|---------------------|--|
| 9 | 25.04.2023 | Maternify | ESP | Healthcare Services | Maternity Care / Undisclosed | Provider of healthcare services intended to offer maternity care. | - | < 1 | < 1 | The company raised EUR 460,000 of angel funding on April 25, 2023. |
| 10 | 24.04.2023 | CheckEye | UKR | HealthTech | Health Application / On market | Operator of health technology company intended to detect diabetic retinopathy using photographic images of eye fund. | - | 1 | 1 | The company joined an Accelerator on April 24, 2023. |
| 11 | 22.04.2023 | Northern Leaf | GBR | Biotech / Pharma | Other / On Market | Producer of medical cannabis intended to provide pharmaceutical-grade flowers and oils. | C | 3 | 23 | The company raised GBP 3 million of venture funding on April 22, 2023. |
| 12 | 20.04.2023 | Follow Health | FRA | HealthTech | Healthcare Application / On market | Developer of a healthcare application intended to manage health consultations and monitor patients. | B | < 1 | 4 | The company raised EUR 922,699 of venture funding on April 20, 2023, putting the company's pre-money valuation at EUR 6.61 million. |
| 13 | 20.04.2023 | miDiagnostics | BEL | MedTech | Medical Device / On market | Developer of chip-based technology designed to bring miniaturized lab-quality tests with built-in connectivity. | D | 10 | 146 | The company raised EUR 10 million of venture funding on April 20, 2023. The funds will be used for its testing platform, including tests for STDs, vaginitis and herpes. |
| 14 | 20.04.2023 | OSO-AI | FRA | HealthTech | AI Noise Technology / On market | Developer of artificial intelligence technology intended to identify noises in the surroundings. | A | 10 | 14 | The company raised EUR 10 million of venture funding on April 20, 2023. The funds will be used to boost sales of its augmented ear for caregivers. |
| 15 | 20.04.2023 | Pharmacierge | GBR | Healthcare Services | Digital Pharmacy Platform / On Market | Developer of digital e-prescribing service platform designed to deliver medication through a digital portal. | A | 3 | 4 | The company raised GBP 2.4 million of venture funding on April 20, 2023. The funds will be used to power company's next phase of growth combining dispensing robotics with AI to manage the vast range of medicines it supplies. |
| 16 | 20.04.2023 | Wearable Robotics | ITA | MedTech | Medical Robotics / On Market | Manufacturer and developer of wearable robotic systems and exoskeletons designed for new resolutions for robotic-aided training and rehabilitation, assistance, and human-power augmentation. | A | 3 | 3 | The company raised EUR 2.5 million of venture funding on April 20, 2023. |


Source: PitchBook as of 05-05-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

| # | Company | HQ | Deal Volume | Series |
|---|----------------------|----|-------------|--------|
| 1 | Distalton | CH | 138 | F |
| 2 | Amolyt Pharma | FR | 130 | C |
| 3 | Hemab Therapeutics | DK | 125 | B |
| 4 | Noema Pharma | CH | 104 | B |
| 5 | Alentis Therapeutics | CH | 97 | C |

Top 5 Investors

| # | Investor | HQ | Deal Volume ² | # of Deals |
|---|----------------------------------|----|--------------------------|------------|
| 1 | Revival Healthcare Capital | US | 138 | 1 |
| 2 | Novo Holdings | DK | 64 | 5 |
| 3 | Gilde Healthcare Partners | DK | 55 | 4 |
| 4 | European Innovation Council Fund | DE | 48 | 9 |
| 5 | Jeito | DK | 46 | 3 |

| # | Date | Company | HQ | Subsector | Vertical - Indication / Stage | Company Description | Series | Deal Volume (EURm) | Total Raised (EURm) | Deal Synopsis |
|----|------------|----------------------|-----|------------------|---|---|--------|--------------------|---------------------|--|
| 17 | 19.04.2023 | Distalton | CH | MedTech | Surgical Device / On market | Manufacturer of a surgical device intended to eliminate the complexity of robotic surgery. | F | 138 | 225 | The company raised \$150 million of venture funding on April 19, 2023. The funds will be used to enable the way for US Food and Drug Administration (FDA) approval and to continue acceleration of clinical experience in Europe. |
| 18 | 19.04.2023 | Ervita | ESP | HealthTech | Online Healthcare Platform / On market | Developer of an online healthcare platform intended to digitize and connect in a timeline where old people require sufficient care. | A | < 1 | < 1 | The company raised EUR 500,000 of venture funding on April 19, 2023. The funds will be used to double its professional team, reaching ten workers, and expand its business portfolio, achieving a greater presence in day centers and residences and entering homes. |
| 19 | 18.04.2023 | Ariceum | DEU | Biotech / Pharma | Oncology / Phase I | Developer of novel drugs designed for systemic targeted radiotherapy. | A | 48 | 48 | The company raised EUR 47.75 million of Series A venture funding on April 18, 2023. The funds will be used to advance the lead radiopharmaceutical product for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers and to advance clinical pipeline. |
| 20 | 18.04.2023 | Vect-Horus | FRA | Biotech / Pharma | Other / Undisclosed | Developer of a targeted drug delivery system intended to enhance the transport of biotherapeutics across biological barriers. | E | 5 | 30 | The company raised EUR 5.00 million of venture funding on April 18, 2023, putting the company's pre-money valuation at EUR 43.53 million. |
| 21 | 18.04.2023 | ART Health Solutions | GBR | HealthTech | Data Insight Platform / On market | Developer of a data insights platform intended to optimize employee health and performance. | A | 2 | 3 | The company raised GBP 1.88 million of venture funding on April 18, 2023, putting the company's pre-money valuation at GBP 2.82 million. The funds will be used to further enhance the product's mobile application and create around 10 new jobs in their Newcastle-based company. |
| 22 | 18.04.2023 | Teint | SWE | MedTech | Plasters / On market | Designer of skin tone-adapted plasters intended to design sustainable products adapted to a diverse society. | A | < 1 | < 1 | The company raised SEK 2.2 million of venture funding on April 18, 2023. |
| 23 | 17.04.2023 | Scan.com | GBR | HealthTech | Diagnostic Imaging Platform / On Market | Developer of a diagnostic imaging platform designed to make medical imaging more accessible. | A | 11 | 17 | The company raised GBP 10 million of Series A venture funding on April 17, 2023. |
| 24 | 14.04.2023 | CHARM Therapeutics | GBR | Biotech / Pharma | Other / Undisclosed | Developer of a deep learning platform intended to deliver medicines of transformational efficacy for patients. | A | 18 | 64 | The company raised \$20.05 million of Series A venture funding on April 14, 2023. |


Source: PitchBook as of 05-05-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

| # | Company | HQ | Deal Volume | Series |
|---|----------------------|----|-------------|--------|
| 1 | Distalton | CH | 138 | F |
| 2 | Amolyt Pharma | FR | 130 | C |
| 3 | Hemab Therapeutics | DK | 125 | B |
| 4 | Noema Pharma | CH | 104 | B |
| 5 | Alentis Therapeutics | CH | 97 | C |

Top 5 Investors

| # | Investor | HQ | Deal Volume ² | # of Deals |
|---|----------------------------------|----|--------------------------|------------|
| 1 | Revival Healthcare Capital | US | 138 | 1 |
| 2 | Novo Holdings | DK | 64 | 5 |
| 3 | Gilde Healthcare Partners | DK | 55 | 4 |
| 4 | European Innovation Council Fund | DE | 48 | 9 |
| 5 | Jeito | DK | 46 | 3 |

| # | Date | Company | HQ | Subsector | Vertical - Indication / Stage | Company Description | Series | Deal Volume (EURm) | Total Raised (EURm) | Deal Synopsis |
|----|------------|----------------------|-----|------------------|---------------------------------------|---|--------|--------------------|---------------------|--|
| 25 | 14.04.2023 | Pear Bio | GBR | Biotech / Pharma | Oncology / Undisclosed | Developer of proprietary biomedical technologies designed for the treatment of cancer through the measurement of drug resistance in patients. | A | 13 | 17 | The company raised \$14.15 million of venture funding on April 14, 2023. |
| 26 | 14.04.2023 | SynaptixBio | GBR | Biotech / Pharma | Central Nervous System / Developing | Operator of a biotech company intended to disrupt current treatment practices for severe leukodystrophies by the development of a therapy that tackles the root of the disease and has the potential to be curative. | A | 13 | 18 | The company raised GBP 11.05 million of venture funding on April 14, 2023. The funds will be used for the company's research treatment and taking it to human clinical trials next year. |
| 27 | 13.04.2023 | Alentis Therapeutics | CHE | Biotech / Pharma | Metabolic Disorders / Phase I | Developer of novel medications designed for the treatment of fibrotic diseases. | C | 97 | 163 | The company raised \$105 million of Series C venture funding on April 13, 2023. The funds will be used to support the clinical development of the company's lead investigational products ALE.F02 and ALE.C04 as well as the CLDN1 platform development. |
| 28 | 13.04.2023 | Neuromod | IRL | MedTech | Medical Device / On market | Developer of a medical technology designed to stimulate progress through the design, clinical validation, and commercialization of neuromodulation technologies. | 2 | 30 | 51 | The company raised EUR 30 million Series B2 of venture funding on April 13, 2023. The funds will be used to expand the availability of its tinnitus treatment in the US and Europe. |
| 29 | 12.04.2023 | Virtonomy | DEU | HealthTech | Medical Application / On Market | Provider of data-driven studies focused on virtual patients intended to shorten the time taken by medical products to reach the market. | A | 4 | 5 | The company raised EUR 3.5 million of venture funding on April 12, 2023. The funds will be used to Help Medical Technology Companies Use Digital Twin Technology to Accelerate Time to Market for Medical Devices. |
| 30 | 11.04.2023 | 2Eyes Vision | ESP | MedTech | Diagnostic Medical Device / On market | Developer of creation and marketing of ophthalmic technologies designed to create tools for the ophthalmic sector, with a particular focus on presbyopia, an eye ailment that affects everyone over the age of 45 and everyone who requires cataract surgery. | C | < 1 | 5 | The company raised EUR 538,000 of venture funding on April 11, 2023. |
| 31 | 11.04.2023 | Adoram Therapeutics | CHE | Biotech / Pharma | Oncology / Undisclosed | Developer of allosteric modulators designed to offer a validated cancer immunotherapy target, A2AR. | - | < 1 | < 1 | The company joined an Accelerator on April 11, 2023 and received CHF 10,000 in funding in the form of grant. |
| 32 | 07.04.2023 | Roca Therapeutics | FRA | Biotech / Pharma | Oncology / Pre-clinic | Developer of biotechnology platform intended to create an innovative therapy to give a new life and vision to patients. | A | < 1 | 2 | The company raised EUR 559,500 of venture funding on April 7, 2023, putting the company's pre-money valuation at EUR 7.50 million. |


Source: PitchBook as of 05-05-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

| # | Company | HQ | Deal Volume | Series |
|---|----------------------|----|-------------|--------|
| 1 | Distalmotion | CH | 138 | F |
| 2 | Amolyt Pharma | FR | 130 | C |
| 3 | Hemab Therapeutics | DK | 125 | B |
| 4 | Noema Pharma | CH | 104 | B |
| 5 | Alentis Therapeutics | CH | 97 | C |

Top 5 Investors

| # | Investor | HQ | Deal Volume ² | # of Deals |
|---|----------------------------------|----|--------------------------|------------|
| 1 | Revival Healthcare Capital | US | 138 | 1 |
| 2 | Novo Holdings | DK | 64 | 5 |
| 3 | Gilde Healthcare Partners | DK | 55 | 4 |
| 4 | European Innovation Council Fund | DE | 48 | 9 |
| 5 | Jeito | DK | 46 | 3 |

| # | Date | Company | HQ | Subsector | Vertical - Indication / Stage | Company Description | Deal Series | Deal Volume (EURm) | Total Raised (EURm) | Deal Synopsis |
|----|------------|---------------------|-----|----------------|--|---|-------------|--------------------|---------------------|---|
| 33 | 06.04.2023 | Biogit | IRL | HealthTech | Medical Platform / On market | Developer of a scientific literature monitoring platform designed to simplify the detection of adverse events from drug development to post-market. | B | < 1 | 2 | The company raised EUR 874,943 of venture funding on April 6, 2023, putting the company's pre-money valuation at EUR 4.27 million. |
| 34 | 05.04.2023 | IntraBio | GBR | Biotech/Pharma | Central Nervous System/ Pre-clinic | Developer of small-molecule therapies intended to offer treatment for rare and neurodegenerative diseases. | C | 14 | 23 | The company raised \$15 million of Series C venture funding on April 5, 2023. The funds will be used to support the company's ongoing Phase III Pivotal trial (IB1001-301) with IB1001 (N-acetyl-L-leucine), and to prepare IB1001 for US New Drug Application (NDA) and European Marketing Authorization Application (MAA) for NPCs. |
| 35 | 05.04.2023 | Piur Imaging | AUT | MedTech | Tomographic Ultrasound Technology / On market | Developer of a tomographic ultrasound technology designed to make vascular imaging affordable and safe. | A | 4 | 4 | The company raised EUR 3.5 million of Series A venture funding on April 5, 2023. |
| 36 | 05.04.2023 | Nanoverly | GBR | Biotech/Pharma | Other / On market | Developer of AI-powered nanorobot platform designed to diagnose the world's deadliest diseases with just a blood sample. | C | 2 | 4 | The company raised GBP 1.85 million of venture funding on April 5, 2023. |
| 37 | 04.04.2023 | Adcendo | DNK | Biotech/Pharma | Oncology / Developing | Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. | A | 82 | 83 | The company raised EUR 82 million of Series A venture funding on April 4, 2023, putting the company's pre-money valuation at EUR 81.84 million. The funding will be used to initiate a broad clinical development program for uPARAP ADC in Sarcoma and is also planning to advance the development of its 2nd ADC pipeline asset with Development Candidate Nomination (DCN) planned in H1 2024. |
| 38 | 04.04.2023 | Mosaic TX | GBR | Biotech/Pharma | Oncology / Developing | Operator of an oncology therapeutics company intended to tackle cancers with substantial unmet needs. | A | 26 | 37 | The company raised \$28 million of Series A venture funding on April 4, 2023. The funds will be used to further advance pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies and will also support recruitment efforts, building the Company's senior leadership, experimental biology, and computational teams. |
| 39 | 04.04.2023 | Caristo Diagnostics | GBR | HealthTech | Cardiovascular Diagnostic System / Undisclosed | Developer of imaging-based and AI-assisted cardiovascular diagnostic platform designed to predict and spot coronary heart conditions. | A | 15 | 27 | The company raised GBP 13 million of Series A venture funding on April 4, 2023. The funds will be used to advance its technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets. |
| 40 | 04.04.2023 | Clue | DEU | MedTech | Fertility Application / On market | Developer of a mobile application designed to track the fertility cycle. | D | 7 | 64 | The company raised EUR 7 million of venture funding on April 4, 2023. The funds will be used to scale Clue's innovative digital family planning offering, expand the product portfolio, and continue much-needed research efforts to close the gender data gap. |


Source: PitchBook as of 05-05-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

| # | Company | HQ | Deal Volume | Series |
|---|----------------------|----|-------------|--------|
| 1 | Distalmotion | CH | 138 | F |
| 2 | Amolyt Pharma | FR | 130 | C |
| 3 | Hemab Therapeutics | DK | 125 | B |
| 4 | Noema Pharma | CH | 104 | B |
| 5 | Alentis Therapeutics | CH | 97 | C |

Top 5 Investors

| # | Investor | HQ | Deal Volume ² | # of Deals |
|---|----------------------------------|----|--------------------------|------------|
| 1 | Revival Healthcare Capital | US | 138 | 1 |
| 2 | Novo Holdings | DK | 64 | 5 |
| 3 | Gilde Healthcare Partners | DK | 55 | 4 |
| 4 | European Innovation Council Fund | DE | 48 | 9 |
| 5 | Jeito | DK | 46 | 3 |

| # | Date | Company | HQ | Subsector | Vertical - Indication / Stage | Company Description | Series | Deal Volume (EURm) | Total Raised (EURm) | Deal Synopsis |
|----|------------|------------|-----|------------------|--|--|--------|--------------------|---------------------|---|
| 41 | 04.04.2023 | Medherant | GBR | Biotech / Pharma | Dermatology / On market | Developer of a novel drug-in-adhesive transdermal delivery system designed to deliver higher doses of drugs through the skin. | E | 3 | 16 | The company raised GBP 3 million of venture funding on April 4, 2023. The funds will be used to accelerate growth and research efforts. |
| 42 | 04.04.2023 | PathoQuest | FRA | Biotech / Pharma | Other / On market | Developer of a molecular diagnostics technology designed to improve pathogen detection in biological samples. | C | 3 | 43 | The company raised EUR 2.57 million of venture funding on April 4, 2023, putting the company's pre-money valuation at EUR 18.85 million. |
| 43 | 04.04.2023 | Bioliberty | GBR | MedTech | Medical Device / Developing | Developer of assistive robotics and rehabilitative technologies designed to empower every human to live a longer independent life. | B | 2 | 3 | The company raised GBP 2.2 million of venture funding on April 4, 2023. The funds will be used to complete the development of the glove's trial product, finalize the development of the Digital Therapy Platform and also fund the business by obtaining FDA approval, and early commercial engagement with U.S. rehabilitation clinics. |
| 44 | 04.04.2023 | Synaptiq | ROU | HealthTech | Medical Application / On market | Developer of a technology platform designed to provide remedies for enhancing the quality of medical services. | A | < 1 | < 1 | The company raised EUR 440,000 of venture funding on April 4, 2023. |
| 45 | 03.04.2023 | InSphero | CHE | Biotech / Pharma | Other / On market | Provider of 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology designed to deliver biologically relevant insights for in vitro testing. | E | 25 | 57 | The company raised CHF 25.00 million of venture funding on April 3, 2023, putting the company's pre-money valuation at CHF 88.74 million. The funds will be used to commercialize 3D microtissue technology and set up the world's largest biobank for pharmaceutical research. |
| 46 | 03.04.2023 | T-Heart | FRA | MedTech | Heart Valve Replacement System / Undisclosed | Developer of a heart valve replacement system intended to provide treatment of severe tricuspid regurgitation for patients suffering from heart problems. | D | 4 | 12 | The company raised EUR 3.5 million of venture funding on April 3, 2023, putting the company's pre-money valuation at EUR 11.65 million. |
| 47 | 01.04.2023 | STIL | NLD | MedTech | Therapeutic Device / On market | Developer of a medical device designed to assist in curbing involuntary tremors in the arm. | B | 5 | 5 | The company raised EUR 4.6 million of venture funding in approximately April 2023. The funds will be used by the company to ready for scaling up their device internationally. |
| 48 | 01.04.2023 | E-Surgery | GBR | HealthTech | Online Health Hub / On market | Developer of an online health hub platform designed to offer patients paperless prescriptions and delivery. | A | 1 | 1 | The company raised GBP 1.05 million of venture funding on April 1, 2023, putting the company's pre-money valuation at GBP 8.70 million. |


Source: PitchBook as of 05-05-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

| # | Company | HQ | Deal Volume | Series |
|---|----------------------|-------------|-------------|--------|
| 1 | Distalmotion | Switzerland | 138 | F |
| 2 | Amolyt Pharma | France | 130 | C |
| 3 | Hemab Therapeutics | Denmark | 125 | B |
| 4 | Noema Pharma | Switzerland | 104 | B |
| 5 | Alentis Therapeutics | Switzerland | 97 | C |

Top 5 Investors

| # | Investor | HQ | Deal Volume ² | # of Deals |
|---|----------------------------------|---------|--------------------------|------------|
| 1 | Revival Healthcare Capital | USA | 138 | 1 |
| 2 | Novo Holdings | Denmark | 64 | 5 |
| 3 | Gilde Healthcare Partners | Denmark | 55 | 4 |
| 4 | European Innovation Council Fund | Germany | 48 | 9 |
| 5 | Jeito | Denmark | 46 | 3 |

| # | Date | Company | HQ | Subsector | Vertical - Indication / Stage | Company Description | Series | Deal Volume (EURm) | Total Raised (EURm) | Deal Synopsis |
|----|------------|----------------|-----|---------------------|---|--|--------|--------------------|---------------------|--|
| 49 | 01.04.2023 | Healthpath | GBR | Healthcare Services | Healthcare Testing Services / On market | Provider of healthcare testing services intended to find the underlying reasons for the patient's symptoms. | C | 1 | 2 | The company raised GBP 1.02 million of venture funding on April 1, 2023, putting the company's pre-money valuation at GBP 10.79 million. |
| 50 | 01.04.2023 | Kimialys | FRA | Biotech / Pharma | Other / On market | Developer of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors. | A | 1 | 1 | The company raised EUR 1 million of venture funding on April 1, 2023. |
| 51 | 01.04.2023 | TRAK | ESP | HealthTech | Telerehabilitation Software / On market | Developer of telerehabilitation software designed to prescribe therapeutic exercise to patients and monitor their treatment. | - | < 1 | < 1 | The company joined an Accelerator in approximately April 2023 and received EUR 150,000 in funding. |
| 52 | 01.04.2023 | Optima Nanomed | GBR | Biotech / Pharma | Other / Undisclosed | Developer of advanced nanomaterials technology designed to offer improved drug delivery into tissues that are hard to target or penetrate by conventional drugs and methods. | - | < 1 | < 1 | The company received GBP 6,000 in funding in approximately April 2023. |

Source: PitchBook as of 05-05-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Contact Details & Disclaimer



FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299
info@fcf.de ▪ www.fcf.de

Arno Fuchs

Chief Executive Officer

P: +49 (89) 206 0409-100
M: +49 (172) 863 6777
arno.fuchs@fcf.de

Dr. Mathias Schott

Advisor Life Sciences

P: +49 (89) 206 0409-123
M: +49 (174) 301 1846
mathias.schott@fcf.de

Johannes Link

Analyst

P: +49 (89) 206 0409-150
M: +49 (172) 839 5746
johannes.link@fcf.de

Marcel Louis Christou

Junior Analyst

P: +49 (89) 206 0409-127
marcellouis.christou@fcf.de

DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2023



THE FINANCING SPECIALIST